Compare INHD & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INHD | BGLC |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | Hong Kong | Malaysia |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 10.1M |
| IPO Year | 2023 | 2019 |
| Metric | INHD | BGLC |
|---|---|---|
| Price | $1.07 | $2.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 120.3K | 8.4K |
| Earning Date | 05-01-2026 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.61 | ★ 45.78 |
| EPS | ★ N/A | N/A |
| Revenue | $2,846,250.00 | ★ $9,510,646.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 221.43 | N/A |
| 52 Week Low | $0.06 | $0.23 |
| 52 Week High | $15.90 | $15.19 |
| Indicator | INHD | BGLC |
|---|---|---|
| Relative Strength Index (RSI) | 46.91 | 53.66 |
| Support Level | $1.07 | $2.12 |
| Resistance Level | $1.18 | $2.73 |
| Average True Range (ATR) | 0.06 | 0.15 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 40.54 | 75.01 |
Inno Holdings Inc is a building technology company with a mission to transform the construction industry with its proprietary cold-formed steel-framing technology and other innovations. It is a manufacturer of cold-formed-steel members and prefabricated homes. It offers a full range of services required to transform raw materials into precise steel framing products and prefabricated homes. The company sells these finished products either to businesses or directly to customers. The finished products and cold-formed-steel members are used in a variety of building types, including residential, commercial, industrial and infrastructure.
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.